Literature DB >> 2846506

Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals.

A Reinberg1, M H Smolensky, G E D'Alonzo, J P McGovern.   

Abstract

Synthetic corticosteroids are frequently used to manage asthma and other inflammatory diseases. The timing of such drugs (whether ingested, inhaled, or infused) in relation to body rhythms influences the magnitude of both desired and undesired effects. It is crucial that corticotherapy be correctly scheduled to the circadian system of the hypothalamic-pituitary-adrenocortical (HPA) system. The secretion of cortisol from the adrenal cortex is not constant during each 24-hour period. Instead, production of this hormone varies as a high-amplitude circadian rhythm, with most of the secretion taking place during the initial hours of the activity span and very little late in the evening and during the first half of the sleep span. Results of laboratory and human studies indicate that the timing of exogenous corticosteroids, in relation to the circadian rhythm in HPA activity, is a critical factor. For example, the optimization of corticosteroid therapy for asthmatics entails daily (or alternate-day) administrations in the morning and, if necessary, early afternoon. By timing exogenous corticosteroids early during the activity span, the risk of adrenal suppression is minimized or avoided while bronchial patency is optimally enhanced, i.e., increasing the 24-hour average forced expiratory volume in 1 second (FEV1) and reducing its nocturnal dip. Clinical findings indicate that these results are obtainable with both acute and chronic corticosteroid therapies. In contrast, splitting the daily dose of corticosteroids into several small administrations, such as at mealtimes and before bedtime, markedly increases the likelihood of adrenal suppression without achieving the desired therapeutic effect. The dosing of synthetic corticosteroids late in the afternoon or evening, whatever the route of delivery, suppresses pituitary adrenocorticotropic hormone (ACTH) production during subsequent 24-hour spans, resulting in adrenocortical inhibition. Also, morning dosing of corticosteroids over many years seems to induce less--if any--osteopenia compared to dosing at other times. The adrenal response to exogenous administration of ACTH also is circadian-rhythmic. ACTH dosing in the morning results in greatest adrenal response in terms of cortisol secretion, while dosing in the evening results in least response. Knowledge of the circadian organization of the HPA axis is necessary to optimize the effect of synthetic corticosteroids, whether they be used to treat asthma, rheumatoid arthritis or other cortico-dependent diseases, or as a substitution therapy for Addison's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846506     DOI: 10.3109/02770908809071368

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  9 in total

1.  Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety.

Authors:  Shigehiro Ohdo
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.

Authors:  M Campieri; A Ferguson; W Doe; T Persson; L G Nilsson
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

3.  A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects.

Authors:  N Andersson; A Källén; L Thorsson
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

4.  Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver.

Authors:  Z X Xu; Y N Sun; D C DuBois; R R Almon; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

Review 5.  Drug-induced sleep disturbances. Focus on nonpsychotropic medications.

Authors:  M Novak; C M Shapiro
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

6.  Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.

Authors:  L E Fisher; E A Ludwig; J A Wald; R R Sloan; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

7.  Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial.

Authors:  Ashley Woodcock; Eric D Bateman; William W Busse; Jan Lötvall; Neil G Snowise; Richard Forth; Loretta Jacques; Brett Haumann; Eugene R Bleecker
Journal:  Respir Res       Date:  2011-10-06

Review 8.  Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications.

Authors:  M H Smolensky; A Reinberg; G Labrecque
Journal:  J Allergy Clin Immunol       Date:  1995-05       Impact factor: 10.793

9.  Circadian Influences on Chemotherapy Efficacy in a Mouse Model of Brain Metastases of Breast Cancer.

Authors:  William H Walker; Samuel A Sprowls; Jacob R Bumgarner; Jennifer A Liu; O Hecmarie Meléndez-Fernández; James C Walton; Paul R Lockman; A Courtney DeVries; Randy J Nelson
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.